Current Coverage Archives

Cantor Fitzgerald Analyst Report Highlights Eupraxia’s Market Potential Post Successful Funding – ( $EPRX $IBB $XBI )

by Vista Partners LLC October 1, 2025 569Views 0Likes

Eupraxia Pharmaceuticals (NASDAQ: EPRX) has catapulted into the biotech spotlight following an influential analyst report from Cantor Fitzgerald that reaffirmed its “Overweight” rating and set a robust $11 price target—nearly double the recent public offering price. This endorsement comes on the heels…

Join The Tribe Public CEO Series: “Sabotage or Success: Discover How Your Mind Awaits Your Orders” – (Oct. 1, 2025 – 11:30am ET)

by John F. Heerdink, Jr. September 30, 2025 471Views 0Likes

Tribe Public extends its appreciation to members who have already registered for this week’s CEO Presentation and Q&A Webinar, scheduled for Wednesday, October 1, at 8:30 a.m. PT / 11:30 a.m. ET. The session, titled “Sabotage or Success: Discover How Your Mind Awaits…

Jennifer Garner’s Once Upon a Farm Files for NYSE IPO: Transforming Kids’ Nutrition with Farm-Fresh Values – ( $OFRM $GS $JPM $BAC )

by John F. Heerdink, Jr. September 29, 2025 720Views 0Likes

Once Upon a Farm, the organic baby and kids’ food pioneer co-founded by actress Jennifer Garner, officially filed for an initial public offering on the New York Stock Exchange this week, signaling a remarkable milestone for a brand that has fused celebrity…

Opendoor’s Stock Soars 330%: Inside the Meme-Fueled Turnaround and CEO Shakeup – ( $OPEN $CVNA $SHOP )

by John F. Heerdink, Jr. September 24, 2025 533Views 0Likes

Opendoor Technologies (NASDAQ: OPEN) has staged one of the year's more improbable turnarounds on Wall Street, propelled as much by operational pivots as by waves of speculative investor fervor. Once flirting with delisting, the online real estate platform recently notched a one-year…

Eupraxia Pharmaceuticals Seeks To Propel Biotech Innovation With $70 Million Funding, EoE Trial Advances – ( $EPRX $IBB $XBI )

by John F. Heerdink, Jr. September 23, 2025 426Views 0Likes

Eupraxia Pharmaceuticals (NASDAQ: EPRX), a clinical-stage biotechnology company developing targeted therapies that leverage a proprietary extended-release delivery system to provide the right dose of a drug, in the right place, for the right amount of time, has recently become a headline act…

U.S. Based GeoVax Labs Seeks To Challenge Bavarian Nordic’s Vaccine Monopoly Amid $3 Billion Buyout – ( $GOVX $BVNKF $IBB $XBI )

by John F. Heerdink, Jr. September 22, 2025 532Views 0Likes

GeoVax Labs, Inc. (NASDAQ: GOVX), an American clinical-stage biotechnology company, is advancing its Modified Vaccinia Ankara (MVA) vaccine platform, positioning itself as a key domestic alternative to Europe's Bavarian Nordic in addressing critical global health threats such as Mpox and smallpox. This…

How Mega-Cap Stocks and Artificial Intelligence Are Redefining the S&P 500

by John F. Heerdink, Jr. September 21, 2025 522Views 0Likes

The S&P 500’s historic ascent in 2025 is forcing market veterans to rethink old assumptions about the drivers of U.S. equities, as Wall Street strategists point to persistent profit growth, expanding margins, and the relentless pace of artificial intelligence investment as key…

Nuclear Power’s $10T Boom: How SMRs & AI Are Fueling a Global Energy Revolution – ( $SMR $OKLO )

by John F. Heerdink, Jr. September 21, 2025 621Views 0Likes

Nuclear power is experiencing a global renaissance, rapidly transforming both market sentiment and energy infrastructure as it claims a central role in addressing the world’s surging electricity needs. Policymakers, investors, and tech giants alike now recognize atomic energy as a strategic asset,…

Biotech Booms: Roche’s 89bio Deal Spurs Sector Rally, Eupraxia (EPRX) Rides Positive Momentum ( $ETNB $RHHBY $IBB $XBI )

by John F. Heerdink, Jr. September 18, 2025 468Views 0Likes

Roche’s headline-grabbing agreement to acquire 89bio (ETNB) in a deal valued at up to $3.5 billion marks a significant moment in the fast-evolving cardiometabolic and liver disease therapeutic sector, underscoring mounting competition for late-stage pipeline assets targeting Metabolic Dysfunction-Associated Steatohepatitis (MASH). As…

Lyft Teams Up with Alphabet’s Waymo for Nashville Robotaxi Rollout—Here’s the Timeline and Impact – ( $AMZN $LYFT $GOOG $TSLA $UBER $BIDU )

by John F. Heerdink, Jr. September 17, 2025 628Views 0Likes

Waymo, Alphabet’s (GOOG) autonomous driving division, is deepening its push into commercial robotaxi operations through a new partnership with Lyft to launch driverless ride-hailing services in Nashville, Tennessee, beginning in 2026. In a joint announcement, the companies revealed that testing of Waymo’s…

Current Coverage

Your Guide To Staying Informed In The Markets